PocketEdge
← All news

Desk note · industry · Pharmaceuticals / consumer health

Mankind Pharma's prescription sales grew fast while its consumer shelf stayed quiet

On 27 October 2026 reporting on the September quarter showed net profit up 39.2% to ₹712 crore and revenue up 17.3% to ₹4,338 crore with a 27% EBITDA margin, yet analysts flagged muted over-the-counter growth despite sharp gains in cardiac, anti-diabetes and gastro portfolios.

27 Oct 2026 · 2 min read

Key takeaways

  • •Mankind Pharma reported September-quarter net profit of ₹712 crore on revenue of ₹4,338 crore, with EBITDA margin at 27%.
  • •Domestic prescription sales grew 15.9% with chronic cardiac and anti-diabetes portfolios rising 19% and 16% respectively.
  • •Several global brokers kept cautious ratings, citing slow over-the-counter growth and valuation even after the earnings beat.

What's going on here?

On 27 October 2026 coverage of Mankind Pharma Ltd’s September-quarter results showed a sharp profit jump to ₹712 crore, up 39.2% year on year, on revenue of ₹4,338 crore that rose 17.3%. EBITDA margin expanded to 27%. The domestic business grew 15.9%, with volume running ahead of the broader Indian pharmaceutical market. Chronic therapies led the way, including 19% growth in cardiac and 16% in anti-diabetes, while acute gastro and VMN segments also posted high-teens gains. Bharat Serums and Vaccines’ domestic specialty unit grew at a steady double-digit pace and exports rose 33%. The over-the-counter franchise, however, delivered only muted growth, and the stock still drew cautious target prices from several global houses despite an intraday rally.

What does this mean?

Mankind built its brand on mass-market consumer products such as condoms and pregnancy kits, so a weak OTC quarter stands out against a strong prescription engine. Prescription portfolios carry stickier doctor relationships but face price regulation and competition from peers with similar molecules. When brokers keep Underperform or Neutral calls after a beat, they are usually arguing that the market already prices in fast chronic growth and that consumer recovery is delayed. Management’s own margin guidance for financial year 2027 in the mid-26% range suggests limited room for further expansion unless OTC reaccelerates or costs ease.

Why should I care?

If you compete in OTC aisles, watch whether Mankind redirects marketing rupees toward chronic brands at the expense of shelf space fights in chemists. Hospital and clinic suppliers benefit when cardiac and diabetes lines outgrow the market, but tenders can tighten if rivals discount. Investors should separate one-day earnings reactions from broker targets that embed OTC assumptions. Follow the next consumer growth guidance update, festive stocking data for OTC brands, and whether management deploys cash from prescription cash flows into acquisitions such as the recent European cell-therapy bet.

More desk notes

Disclaimer

For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.